HighTower Advisors LLC lifted its holdings in shares of InVitae Corp (NASDAQ:NVTA) by 4.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 265,095 shares of the medical research company’s stock after purchasing an additional 12,351 shares during the period. HighTower Advisors LLC owned about 0.61% of InVitae Corp worth $2,535,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Verity Asset Management Inc. raised its stake in shares of InVitae Corp by 0.8% during the 2nd quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock worth $101,000 after purchasing an additional 81 shares during the period. Donald L. Hagan LLC raised its stake in shares of InVitae Corp by 30.0% during the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock worth $124,000 after purchasing an additional 3,000 shares during the period. Voya Investment Management LLC raised its stake in shares of InVitae Corp by 51.2% during the 2nd quarter. Voya Investment Management LLC now owns 16,936 shares of the medical research company’s stock worth $162,000 after purchasing an additional 5,733 shares during the period. Nationwide Fund Advisors raised its stake in shares of InVitae Corp by 21.1% during the 1st quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock worth $189,000 after purchasing an additional 2,987 shares during the period. Finally, American International Group Inc. raised its stake in shares of InVitae Corp by 31.3% during the 1st quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after purchasing an additional 4,090 shares during the period.

A number of research firms have recently commented on NVTA. Zacks Investment Research cut InVitae Corp from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. BidaskClub upgraded InVitae Corp from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Finally, J P Morgan Chase & Co restated an “overweight” rating and issued a $15.00 price objective (up from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. InVitae Corp has an average rating of “Hold” and an average target price of $14.33.

Shares of InVitae Corp (NASDAQ:NVTA) opened at 9.89 on Friday. InVitae Corp has a 52 week low of $5.76 and a 52 week high of $10.96. The company’s market capitalization is $430.65 million. The company has a 50-day moving average price of $9.31 and a 200-day moving average price of $9.31.

InVitae Corp (NASDAQ:NVTA) last posted its earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The firm had revenue of $14.34 million during the quarter, compared to the consensus estimate of $13.31 million. During the same period in the prior year, the company posted ($0.77) EPS. The firm’s revenue was up 157.0% compared to the same quarter last year. Analysts predict that InVitae Corp will post ($2.35) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/invitae-corp-nvta-stake-raised-by-hightower-advisors-llc/1615319.html.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.